3 Aug 2020 07:00
Verona Pharma Announces August 2020 Virtual Investor Conference ParticipationLONDON and RALEIGH, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, and Mark Hahn, Chief Financial Officer, will present a company overview at the following virtual investor conferences in August 2020:
BTIG Virtual Biotechnology Conference Date: Monday, August 10Time: 2:30 PM ET
Wedbush PacGrow Healthcare Virtual ConferenceDate: Wednesday, August 12Time: 11:30 AM ET
40th Annual Canaccord Genuity Growth ConferenceDate: Thursday, August 13Time: 4:30 PM ET
A live webcast of each event will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com, and an audio replay will be available there for 30 days.
About Verona PharmaVerona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma’s product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. Following a response from the U.S. FDA to Verona Pharma’s End-of-Phase 2 briefing package, the Company plans to initiate its Phase 3 clinical program ENHANCE (Ensifentrine as a Novel inHAled Nebulized COPD thErapy) later in 2020 for nebulized ensifentrine for COPD maintenance treatment. The Company raised gross proceeds of $200 million through a private placement in July 2020 and expects the funds to support its operations and Phase 3 clinical program into 2023. Verona Pharma is currently in Phase 2 development with two additional formulations of ensifentrine for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler. Ensifentrine also has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.
| Verona Pharma plc | Tel: +44 (0)20 3283 4200 |
| Victoria Stewart, Director of Communications | info@veronapharma.com |
| N+1 Singer (Nominated Adviser and UK Broker) | Tel: +44 (0)20 3283 4200 |
| Aubrey Powell / George Tzimas / Iqra Amin (Corporate Finance) | |
| Tom Salvesen (Corporate Broking) | |
| Optimum Strategic Communications (European Media and Investor Enquiries) | Tel: +44 (0)20 950 9144 verona@optimumcomms.com |
| Mary Clark / Eva Haas / Shabnam Bashir | |
| Argot Partners (US Investor Enquiries) | Tel: +1 212-600-1902 verona@argotpartners.com |
| Kimberly Minarovich / Michael Barron |